Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112 PET Imaging
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Diagnostic efficacy, survival analysis
Time frame: Completed within half year after end of the study
Eligibility Criteria
Inclusion Criteria: * 1\) Patients aged over 18 years with no gender restriction; * 2\) Patients diagnosed with esophageal cancer; * 3\) Patients eligible for 89Zr-AK112 PET examination; * 4\) Written informed consent signed by the subject or their legal guardian. Exclusion Criteria: * 1\) Patients who have received antitumor therapy prior to PET/CT scanning; * 2\) Patients with severe diseases that cannot tolerate PET/CT scanning; * 3\) Alternative subjects with contraindications to PET/CT scanning; * 4\) Radiation exposure exceeding 50 mSv dose in the past year; * 5\) Alternative subjects who underwent major surgery within the past 3 months; those who received experimental drugs or devices (with unclear efficacy or safety) within the past 1 month; * 6\) Alternative subjects with any clinical conditions that the principal investigator of this study considers may cause or pose potential hazards from the investigational product.
✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →